HRD detection is just our first step toward transforming precision medicine. Homologous Recombination Deficiency (HRD) is a notoriously challenging biomarker for traditional next-generation sequencing (NGS) methods. It often requires substantial tissue samples, suffers from high QNS (Quantity Not Sufficient) rates, and results in frequent delays, inconclusive outcomes, or ambiguous “gray zone” findings. 

Given HRD’s critical role in guiding treatment decisions for high-mortality cancers—such as pancreatic, ovarian, and advanced breast—starting here was a clear and urgent choice. 

But this is only the beginning. 

Our technology unlocks a new era of real-time, tissue-sparing biomarker detection. Beyond HRD, we’re rapidly expanding to other key biomarkers, across a broader range of cancers, and across the clinical care continuum. The same platform holds promise for accelerating clinical trial enrollment, optimizing study design, and driving smarter, faster drug development. 

We’re building more than a tool—we’re building the future of precision medicine. And that future is coming fast.